T Cell Interferon and Cytotoxic Pathways in Axial Spondyloarthritis: Relationship to Secukinumab Response Profiles
Our study aims to define the difference in granzyme (GZMs) expression in axial spondyloarthritis (axSpA) patients that predisposes secukinumab treatment response. Secukinumab treatment response, as determined using BASDAI50 scoring at week 24, stratified patients into responders (SEC-R) and nonresponders (SE...